Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084481 | 1.00 | ACE (0.37) | ACEALDH1A1RENPHGDHKDM4E | |
| SCHEMBL21143535 | 1.00 | ACE (0.37) | ACEALDH1A1RENPHGDHKDM4E | |
| SCHEMBL5320346 | 0.86 | ACE (0.50) | ACEALDH1A1RENKDM4EF2 | |
| SCHEMBL3403871 | 0.85 | ACE (0.37) | ACERENKDM4EF2LMNA | |
| SCHEMBL3403874 | 0.85 | ACE (0.37) | ACERENKDM4EF2LMNA | |
| SCHEMBL27698951 | 0.85 | ACE (0.37) | ACERENKDM4EF2LMNA | |
| SCHEMBL28251167 | 0.83 | PHGDH (0.34) | PHGDHMAPT | |
| SCHEMBL18069335 | 0.81 | PHGDH (0.33) | PHGDHMAPT | |
| SCHEMBL8278733 | 0.81 | PHGDH (0.33) | PHGDHMAPT | |
| SCHEMBL23811259 | 0.79 | EPHX1 (0.35) | PHGDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922392-B | 1- (hetero) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide derivatives and uses thereof | 豪夫迈·罗氏有限公司 | 2020-07-21 | — | — | CN | disclosed |
| CN-109843856-A | KRAS G12C inhibitor | 米拉蒂治疗股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-101965351-A | Benzofuran pyrimidinones | EXELIXIS INC | 2011-02-02 | — | — | CN | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| EP-1888618-A4 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-15 | — | — | EP | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| EP-1888618-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | Neuren Pharmaceuticals Limited (NZ) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | ACE 2424/4885ALDH1A1 574/4885REN 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.